Cargando…

52. PrEP Adherence and Discontinuation at a Pharmacy-Supported PrEP Program in Atlanta, GA

BACKGROUND: Pre-exposure prophylaxis (PrEP) is a highly effective biomedical strategy to decrease Human Immunodeficiency Virus (HIV) acquisition. Effectiveness of oral PrEP is linked to medication adherence. In 2018, Grady Health System (GHS) launched a PrEP program to increase PrEP access among un-...

Descripción completa

Detalles Bibliográficos
Autores principales: Yacout, Hiba, Smith, Bradley L, Foster, Shelbie, Lora, Meredith, Niles-Carnes, Laris, Zheng, Ziduo, Kundu, Suprateek, Gruen, Judah K, Cantos, Valeria D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644284/
http://dx.doi.org/10.1093/ofid/ofab466.052
_version_ 1784610050021523456
author Yacout, Hiba
Smith, Bradley L
Foster, Shelbie
Lora, Meredith
Niles-Carnes, Laris
Zheng, Ziduo
Kundu, Suprateek
Gruen, Judah K
Cantos, Valeria D
author_facet Yacout, Hiba
Smith, Bradley L
Foster, Shelbie
Lora, Meredith
Niles-Carnes, Laris
Zheng, Ziduo
Kundu, Suprateek
Gruen, Judah K
Cantos, Valeria D
author_sort Yacout, Hiba
collection PubMed
description BACKGROUND: Pre-exposure prophylaxis (PrEP) is a highly effective biomedical strategy to decrease Human Immunodeficiency Virus (HIV) acquisition. Effectiveness of oral PrEP is linked to medication adherence. In 2018, Grady Health System (GHS) launched a PrEP program to increase PrEP access among un- and underinsured individuals living in metro Atlanta, Georgia. The purpose of this study is to determine PrEP medication adherence, PrEP discontinuation rates, and associated individual factors of patients enrolled during the first 18 months of the program’s implementation. METHODS: A single-center, retrospective chart review was conducted on patients enrolled in the GHS PrEP program between June 1, 2018 and February 29, 2020 who received more than one monthly PrEP prescription. Adherence was estimated using the medication possession ratio (MPR). The primary outcome was mean adherence to PrEP. Secondary outcomes include rate of high percent adherence (MPR > 80%), median time of engagement in care, PrEP discontinuation rates, rates of PrEP re-engagement, and individual factors associated with PrEP discontinuation and low adherence. RESULTS: This study included 154 patients, 70.8% of them were Black, 62.3% were cisgender men, 59.1% were uninsured, and the mean age was 34. The majority of patients identified as men who have sex with men (51.9%). Mean PrEP adherence was 89.2%; 77.3% of patients demonstrated a high rate of adherence. No individual or social factors were associated with low adherence, but younger age was associated with higher rates of PrEP discontinuation (p< 0.0061). At the end of the follow up period on October 30, 2020, 53.8% of patients were active in the program and 12.7% of those who discontinued had re-engaged with the program. The average length of program engagement was 9.8 months. Table 1. Baseline socio-demographic characteristics (N=154) [Image: see text] Table 2. PrEP Adherence and Discontinuation at the GHS PrEP Program from 2018 to 2020 (N=154) [Image: see text] Table 4. Multivariate analysis of individual factors associated with PrEP discontinuation and low adherence [Image: see text] CONCLUSION: Mean PrEP adherence at a safety net PrEP program in Atlanta was high and PrEP discontinuation rates were comparable to other PrEP clinics nationwide. We found no association with individual factors previously linked to lower adherence, including Black race, younger age, and insurance status. Program-related factors that may have impacted these findings need to be investigated. Other future areas of research include strategies to optimize engagement in care in younger patients. DISCLOSURES: Bradley L. Smith, Pharm.D., AAHIVP, Gilead Sciences, Inc (Advisor or Review Panel member)
format Online
Article
Text
id pubmed-8644284
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-86442842021-12-06 52. PrEP Adherence and Discontinuation at a Pharmacy-Supported PrEP Program in Atlanta, GA Yacout, Hiba Smith, Bradley L Foster, Shelbie Lora, Meredith Niles-Carnes, Laris Zheng, Ziduo Kundu, Suprateek Gruen, Judah K Cantos, Valeria D Open Forum Infect Dis Oral Abstracts BACKGROUND: Pre-exposure prophylaxis (PrEP) is a highly effective biomedical strategy to decrease Human Immunodeficiency Virus (HIV) acquisition. Effectiveness of oral PrEP is linked to medication adherence. In 2018, Grady Health System (GHS) launched a PrEP program to increase PrEP access among un- and underinsured individuals living in metro Atlanta, Georgia. The purpose of this study is to determine PrEP medication adherence, PrEP discontinuation rates, and associated individual factors of patients enrolled during the first 18 months of the program’s implementation. METHODS: A single-center, retrospective chart review was conducted on patients enrolled in the GHS PrEP program between June 1, 2018 and February 29, 2020 who received more than one monthly PrEP prescription. Adherence was estimated using the medication possession ratio (MPR). The primary outcome was mean adherence to PrEP. Secondary outcomes include rate of high percent adherence (MPR > 80%), median time of engagement in care, PrEP discontinuation rates, rates of PrEP re-engagement, and individual factors associated with PrEP discontinuation and low adherence. RESULTS: This study included 154 patients, 70.8% of them were Black, 62.3% were cisgender men, 59.1% were uninsured, and the mean age was 34. The majority of patients identified as men who have sex with men (51.9%). Mean PrEP adherence was 89.2%; 77.3% of patients demonstrated a high rate of adherence. No individual or social factors were associated with low adherence, but younger age was associated with higher rates of PrEP discontinuation (p< 0.0061). At the end of the follow up period on October 30, 2020, 53.8% of patients were active in the program and 12.7% of those who discontinued had re-engaged with the program. The average length of program engagement was 9.8 months. Table 1. Baseline socio-demographic characteristics (N=154) [Image: see text] Table 2. PrEP Adherence and Discontinuation at the GHS PrEP Program from 2018 to 2020 (N=154) [Image: see text] Table 4. Multivariate analysis of individual factors associated with PrEP discontinuation and low adherence [Image: see text] CONCLUSION: Mean PrEP adherence at a safety net PrEP program in Atlanta was high and PrEP discontinuation rates were comparable to other PrEP clinics nationwide. We found no association with individual factors previously linked to lower adherence, including Black race, younger age, and insurance status. Program-related factors that may have impacted these findings need to be investigated. Other future areas of research include strategies to optimize engagement in care in younger patients. DISCLOSURES: Bradley L. Smith, Pharm.D., AAHIVP, Gilead Sciences, Inc (Advisor or Review Panel member) Oxford University Press 2021-12-04 /pmc/articles/PMC8644284/ http://dx.doi.org/10.1093/ofid/ofab466.052 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Oral Abstracts
Yacout, Hiba
Smith, Bradley L
Foster, Shelbie
Lora, Meredith
Niles-Carnes, Laris
Zheng, Ziduo
Kundu, Suprateek
Gruen, Judah K
Cantos, Valeria D
52. PrEP Adherence and Discontinuation at a Pharmacy-Supported PrEP Program in Atlanta, GA
title 52. PrEP Adherence and Discontinuation at a Pharmacy-Supported PrEP Program in Atlanta, GA
title_full 52. PrEP Adherence and Discontinuation at a Pharmacy-Supported PrEP Program in Atlanta, GA
title_fullStr 52. PrEP Adherence and Discontinuation at a Pharmacy-Supported PrEP Program in Atlanta, GA
title_full_unstemmed 52. PrEP Adherence and Discontinuation at a Pharmacy-Supported PrEP Program in Atlanta, GA
title_short 52. PrEP Adherence and Discontinuation at a Pharmacy-Supported PrEP Program in Atlanta, GA
title_sort 52. prep adherence and discontinuation at a pharmacy-supported prep program in atlanta, ga
topic Oral Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644284/
http://dx.doi.org/10.1093/ofid/ofab466.052
work_keys_str_mv AT yacouthiba 52prepadherenceanddiscontinuationatapharmacysupportedprepprograminatlantaga
AT smithbradleyl 52prepadherenceanddiscontinuationatapharmacysupportedprepprograminatlantaga
AT fostershelbie 52prepadherenceanddiscontinuationatapharmacysupportedprepprograminatlantaga
AT lorameredith 52prepadherenceanddiscontinuationatapharmacysupportedprepprograminatlantaga
AT nilescarneslaris 52prepadherenceanddiscontinuationatapharmacysupportedprepprograminatlantaga
AT zhengziduo 52prepadherenceanddiscontinuationatapharmacysupportedprepprograminatlantaga
AT kundusuprateek 52prepadherenceanddiscontinuationatapharmacysupportedprepprograminatlantaga
AT gruenjudahk 52prepadherenceanddiscontinuationatapharmacysupportedprepprograminatlantaga
AT cantosvaleriad 52prepadherenceanddiscontinuationatapharmacysupportedprepprograminatlantaga